ArticleInternational journal of genomics2026
Integrative Bioinformatics and Machine Learning Identify Novel Diagnostic Biomarkers and Molecular Mechanisms in Sjögren's Syndrome.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Bioinformatics and Machine Learning Identify Novel Diagnostic Biomarkers and Molecular Mechanisms in Sjögren's Syndrome.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sjögren's syndrome (SS) is a chronic autoimmune disorder characterized by significant diagnostic challenges due to nonspecific symptoms and a lack of reliable biomarkers, often resulting in delayed diagnosis and suboptimal patient management. Objective: This study is aimed at identifying novel diagnostic biomarkers and elucidating the molecular mechanisms underlying SS pathogenesis through integrative bioinformatics and machine learning approaches. Methods: We analyzed three peripheral blood transcriptomic datasets (GSE51092, GSE66795, and GSE84844) comprising a total of 351 SS patients and 91 healthy controls. Differential expression analysis, weighted gene coexpression network analysis (WGCNA), and 12 machine learning algorithms were employed to identify robust diagnostic biomarkers. Immune cell infiltration was assessed using CIBERSORT, and single-cell RNA sequencing data (GSE157278) were analyzed to validate cell-type-specific expression patterns. Drug repurposing analysis was conducted using the L1000FWD platform. Results: We identified 12 hub genes (EPSTI1, IFIH1, CXCL10, TNFSF10, GBP5, PARP9, IFI44, LAP3, IFIT2, IFI44L, PARP12, and OAS1) with exceptional diagnostic performance (AUC = 0.994 in training, 0.838 in internal validation, and 0.825 in external validation). These biomarkers showed significant correlations with clinical indicators including ANA, Ro/SSA, and La/SSB ( Conclusion: Our integrative approach identifies 12 robust diagnostic biomarkers for SS, offering new insights into disease mechanisms and highlighting potential therapeutic targets for this challenging autoimmune disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.